Roberts Wealth Advisors LLC Sells 300 Shares of Gilead Sciences, Inc. $GILD

Roberts Wealth Advisors LLC reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,635 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Roberts Wealth Advisors LLC’s holdings in Gilead Sciences were worth $514,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Motiv8 Investments LLC lifted its position in Gilead Sciences by 12.0% in the 2nd quarter. Motiv8 Investments LLC now owns 13,191 shares of the biopharmaceutical company’s stock valued at $1,462,000 after acquiring an additional 1,412 shares in the last quarter. Capital Advisors Inc. OK raised its stake in shares of Gilead Sciences by 8.6% in the second quarter. Capital Advisors Inc. OK now owns 2,258 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 179 shares during the last quarter. Valeo Financial Advisors LLC lifted its holdings in shares of Gilead Sciences by 26.7% in the second quarter. Valeo Financial Advisors LLC now owns 13,262 shares of the biopharmaceutical company’s stock valued at $1,470,000 after purchasing an additional 2,795 shares in the last quarter. Knights of Columbus Asset Advisors LLC boosted its position in shares of Gilead Sciences by 1.5% during the second quarter. Knights of Columbus Asset Advisors LLC now owns 28,863 shares of the biopharmaceutical company’s stock valued at $3,200,000 after buying an additional 415 shares during the last quarter. Finally, Merit Financial Group LLC grew its holdings in Gilead Sciences by 64.1% during the second quarter. Merit Financial Group LLC now owns 47,951 shares of the biopharmaceutical company’s stock worth $5,316,000 after buying an additional 18,722 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. UBS Group boosted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Saturday, September 27th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $117.17.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer owned 605,725 shares of the company’s stock, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock worth $9,402,130 over the last 90 days. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Up 0.8%

GILD opened at $113.58 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $84.17 and a twelve month high of $121.83. The company’s 50-day moving average price is $114.36 and its two-hundred day moving average price is $110.01. The stock has a market cap of $140.93 billion, a price-to-earnings ratio of 22.63, a PEG ratio of 0.77 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.